nafcillin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, 6-aminopenicillanic acid derivatives | 1869 | 147-52-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A semi-synthetic antibiotic related to penicillin.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 3 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 27 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 188.60 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 30 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.22 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 3.30 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.13 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 0.70 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 50 mg/mL | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 11, 1965 | FDA | WYETH AYERST |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Tubulointerstitial nephritis | 143.78 | 35.85 | 41 | 740 | 20983 | 34935167 |
| Acute kidney injury | 57.69 | 35.85 | 50 | 731 | 304938 | 34651212 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Tubulointerstitial nephritis | 153.28 | 34.04 | 44 | 1026 | 38191 | 79705127 |
| Acute kidney injury | 62.51 | 34.04 | 53 | 1017 | 519351 | 79223967 |
| Blood creatinine increased | 34.55 | 34.04 | 23 | 1047 | 155034 | 79588284 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01CF06 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Beta-lactamase resistant penicillins |
| FDA CS | M0016152 | Penicillins |
| FDA EPC | N0000175497 | Penicillin-class Antibacterial |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| CHEBI has role | CHEBI:36047 | antibacterial drugs |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Staphylococcal meningitis | indication | 12166008 | |
| Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
| Staphylococcal pneumonia | indication | 22754005 | |
| Staphylococcal infectious disease | indication | 56038003 | |
| Staphylococcal endocarditis | indication | 73028002 | |
| Acute bacterial sinusitis | indication | 75498004 | |
| Infection of bone | indication | 111253001 | |
| Infection due to Staphylococcus aureus | indication | 406602003 | |
| Osteomyelitis due to Staphylococcus aureus | indication | 428783003 | |
| Sepsis due to Staphylococcus aureus | indication | 448417001 | |
| Staphylococcus Aureus Joint Infection | indication | ||
| Staphylococcal Prosthetic Heart Valve Endocarditis | indication | ||
| Pyrexia of unknown origin | off-label use | 7520000 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Infectious mononucleosis | contraindication | 271558008 | DOID:8568 |
| Pseudomembranous enterocolitis | contraindication | 397683000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.76 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Penicillin-binding protein | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Penicillin-binding protein 1A | Enzyme | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4018987 | VUID |
| N0000178981 | NUI |
| D00928 | KEGG_DRUG |
| 7177-50-6 | SECONDARY_CAS_RN |
| 4018987 | VANDF |
| 4019849 | VANDF |
| CHEBI:7447 | CHEBI |
| NFN | PDB_CHEM_ID |
| CHEMBL1443 | ChEMBL_ID |
| CHEMBL1200344 | ChEMBL_ID |
| CHEMBL1568276 | ChEMBL_ID |
| 10942 | IUPHAR_LIGAND_ID |
| 1491 | INN_ID |
| DB00607 | DRUGBANK_ID |
| 4CNZ27M7RV | UNII |
| 218589 | RXNORM |
| 2025 | MMSL |
| 3048 | MMSL |
| 5145 | MMSL |
| d00029 | MMSL |
| 002698 | NDDF |
| 004837 | NDDF |
| 372898000 | SNOMEDCT_US |
| 55435000 | SNOMEDCT_US |
| 91169009 | SNOMEDCT_US |
| C0027324 | UMLSCUI |
| D009254 | MESH_DESCRIPTOR_UI |
| 8982 | PUBCHEM_CID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| NAFCILLIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-1017 | INJECTION, SOLUTION | 1 g | INTRAVENOUS | NDA | 23 sections |
| NAFCILLIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-1017 | INJECTION, SOLUTION | 1 g | INTRAVENOUS | NDA | 23 sections |
| NAFCILLIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-1019 | INJECTION, SOLUTION | 2 g | INTRAVENOUS | NDA | 23 sections |
| NAFCILLIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-1019 | INJECTION, SOLUTION | 2 g | INTRAVENOUS | NDA | 23 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-3713 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 23 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-3714 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 23 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-3715 | INJECTION, POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 23 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3124 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 23 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3125 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 23 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3126 | INJECTION, POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 24 sections |
| Nafcillin Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3128 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 24 sections |
| Nafcillin Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3129 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 24 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-9124 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 23 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-9125 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 23 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-9126 | INJECTION, POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 23 sections |
| Nafcillin Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-9224 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 24 sections |
| Nafcillin Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-9225 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 24 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-139 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 26 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-140 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 26 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-141 | INJECTION, POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 25 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 36000-175 | INJECTION | 1 g | INTRAMUSCULAR | ANDA | 26 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 36000-176 | INJECTION | 2 g | INTRAMUSCULAR | ANDA | 26 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44567-221 | POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 25 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44567-221 | POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 25 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44567-222 | POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 25 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44567-222 | POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 25 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44567-223 | INJECTION, POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 13 sections |
| Nafcillin | Human Prescription Drug Label | 1 | 55150-122 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 23 sections |
| Nafcillin | Human Prescription Drug Label | 1 | 55150-122 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 23 sections |
| Nafcillin | Human Prescription Drug Label | 1 | 55150-123 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 23 sections |